Cargando…
Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
OBJECTIVE: To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: This nationwide cross-sectional study was con...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482550/ https://www.ncbi.nlm.nih.gov/pubmed/34601146 http://dx.doi.org/10.1016/j.ijid.2021.09.062 |
_version_ | 1784576931021193216 |
---|---|
author | Al-Abri, Seif Salem Al-Wahaibi, Adil Al-Kindi, Hanan Kurup, Padmamohan J Al-Maqbali, Ali Al-Mayahi, Zayid Al-Tobi, Mohammed Hamed Al-Katheri, Salim Habbash Albusaidi, Sultan Al-Sukaiti, Mahmood Humaid Al Balushi, Ahmed Yar Mohammed Abdelgadir, Iyad Omer Al-Shehi, Nawal Morkos, Essam Al-Maani, Amal Al-Rawahi, Bader Alyaquobi, Fatma Alqayoudhi, Abdullah Al-Harthy, Khalid Al-Khalili, Sulien Al-Rashdi, Azza Al-Shukri, Intisar Al Ghafri, Thamra S. Al-Hashmi, Fatma Al Jassasi, Saeed Mussalam Alshaqsi, Nasser Mitra, Nilanjan Al Aamry, Humaid Suhail Shah, Parag Al Marbouai, Hanan Hassan Al Araimi, Amany Hamed Kair, Ismail Mohammed Al Manji, Asim Mohammed Almallak, Ahmed Said Al Alawi, Fatma Khamis Vaidya, Vidyanand Muqeetullah, Muhammad Alrashdi, Hanan Al Jamoudi, Saud Said Nassir Alshaqsi, Asila Al Sharji, Abdullah Al Shukeiri, Hamida Al-Abri, Badr Al-Rawahi, Sulaiman Al-Lamki, Said H. Al-Manji, Abdulla Al-Jardani, Amina |
author_facet | Al-Abri, Seif Salem Al-Wahaibi, Adil Al-Kindi, Hanan Kurup, Padmamohan J Al-Maqbali, Ali Al-Mayahi, Zayid Al-Tobi, Mohammed Hamed Al-Katheri, Salim Habbash Albusaidi, Sultan Al-Sukaiti, Mahmood Humaid Al Balushi, Ahmed Yar Mohammed Abdelgadir, Iyad Omer Al-Shehi, Nawal Morkos, Essam Al-Maani, Amal Al-Rawahi, Bader Alyaquobi, Fatma Alqayoudhi, Abdullah Al-Harthy, Khalid Al-Khalili, Sulien Al-Rashdi, Azza Al-Shukri, Intisar Al Ghafri, Thamra S. Al-Hashmi, Fatma Al Jassasi, Saeed Mussalam Alshaqsi, Nasser Mitra, Nilanjan Al Aamry, Humaid Suhail Shah, Parag Al Marbouai, Hanan Hassan Al Araimi, Amany Hamed Kair, Ismail Mohammed Al Manji, Asim Mohammed Almallak, Ahmed Said Al Alawi, Fatma Khamis Vaidya, Vidyanand Muqeetullah, Muhammad Alrashdi, Hanan Al Jamoudi, Saud Said Nassir Alshaqsi, Asila Al Sharji, Abdullah Al Shukeiri, Hamida Al-Abri, Badr Al-Rawahi, Sulaiman Al-Lamki, Said H. Al-Manji, Abdulla Al-Jardani, Amina |
author_sort | Al-Abri, Seif Salem |
collection | PubMed |
description | OBJECTIVE: To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors. RESULTS: In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8–6.2%) in Cycle 1 to 22% (19.6–24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6–10.9%) vs 3.2% (2.6–3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0–27.9%) vs 16.8% (14.9–18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64–2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04–2.35). CONCLUSION: This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity. |
format | Online Article Text |
id | pubmed-8482550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84825502021-09-30 Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys Al-Abri, Seif Salem Al-Wahaibi, Adil Al-Kindi, Hanan Kurup, Padmamohan J Al-Maqbali, Ali Al-Mayahi, Zayid Al-Tobi, Mohammed Hamed Al-Katheri, Salim Habbash Albusaidi, Sultan Al-Sukaiti, Mahmood Humaid Al Balushi, Ahmed Yar Mohammed Abdelgadir, Iyad Omer Al-Shehi, Nawal Morkos, Essam Al-Maani, Amal Al-Rawahi, Bader Alyaquobi, Fatma Alqayoudhi, Abdullah Al-Harthy, Khalid Al-Khalili, Sulien Al-Rashdi, Azza Al-Shukri, Intisar Al Ghafri, Thamra S. Al-Hashmi, Fatma Al Jassasi, Saeed Mussalam Alshaqsi, Nasser Mitra, Nilanjan Al Aamry, Humaid Suhail Shah, Parag Al Marbouai, Hanan Hassan Al Araimi, Amany Hamed Kair, Ismail Mohammed Al Manji, Asim Mohammed Almallak, Ahmed Said Al Alawi, Fatma Khamis Vaidya, Vidyanand Muqeetullah, Muhammad Alrashdi, Hanan Al Jamoudi, Saud Said Nassir Alshaqsi, Asila Al Sharji, Abdullah Al Shukeiri, Hamida Al-Abri, Badr Al-Rawahi, Sulaiman Al-Lamki, Said H. Al-Manji, Abdulla Al-Jardani, Amina Int J Infect Dis Article OBJECTIVE: To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors. RESULTS: In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8–6.2%) in Cycle 1 to 22% (19.6–24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6–10.9%) vs 3.2% (2.6–3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0–27.9%) vs 16.8% (14.9–18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64–2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04–2.35). CONCLUSION: This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-11 2021-09-30 /pmc/articles/PMC8482550/ /pubmed/34601146 http://dx.doi.org/10.1016/j.ijid.2021.09.062 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Al-Abri, Seif Salem Al-Wahaibi, Adil Al-Kindi, Hanan Kurup, Padmamohan J Al-Maqbali, Ali Al-Mayahi, Zayid Al-Tobi, Mohammed Hamed Al-Katheri, Salim Habbash Albusaidi, Sultan Al-Sukaiti, Mahmood Humaid Al Balushi, Ahmed Yar Mohammed Abdelgadir, Iyad Omer Al-Shehi, Nawal Morkos, Essam Al-Maani, Amal Al-Rawahi, Bader Alyaquobi, Fatma Alqayoudhi, Abdullah Al-Harthy, Khalid Al-Khalili, Sulien Al-Rashdi, Azza Al-Shukri, Intisar Al Ghafri, Thamra S. Al-Hashmi, Fatma Al Jassasi, Saeed Mussalam Alshaqsi, Nasser Mitra, Nilanjan Al Aamry, Humaid Suhail Shah, Parag Al Marbouai, Hanan Hassan Al Araimi, Amany Hamed Kair, Ismail Mohammed Al Manji, Asim Mohammed Almallak, Ahmed Said Al Alawi, Fatma Khamis Vaidya, Vidyanand Muqeetullah, Muhammad Alrashdi, Hanan Al Jamoudi, Saud Said Nassir Alshaqsi, Asila Al Sharji, Abdullah Al Shukeiri, Hamida Al-Abri, Badr Al-Rawahi, Sulaiman Al-Lamki, Said H. Al-Manji, Abdulla Al-Jardani, Amina Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys |
title | Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys |
title_full | Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys |
title_fullStr | Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys |
title_full_unstemmed | Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys |
title_short | Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys |
title_sort | seroprevalence of sars-cov-2 antibodies in the general population of oman: results from four successive nationwide sero-epidemiological surveys |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482550/ https://www.ncbi.nlm.nih.gov/pubmed/34601146 http://dx.doi.org/10.1016/j.ijid.2021.09.062 |
work_keys_str_mv | AT alabriseifsalem seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alwahaibiadil seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alkindihanan seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT kuruppadmamohanj seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT almaqbaliali seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT almayahizayid seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT altobimohammedhamed seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alkatherisalimhabbash seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT albusaidisultan seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alsukaitimahmoodhumaid seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT albalushiahmedyarmohammed seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT abdelgadiriyadomer seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alshehinawal seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT morkosessam seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT almaaniamal seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alrawahibader seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alyaquobifatma seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alqayoudhiabdullah seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alharthykhalid seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alkhalilisulien seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alrashdiazza seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alshukriintisar seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alghafrithamras seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alhashmifatma seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT aljassasisaeedmussalam seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alshaqsinasser seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT mitranilanjan seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alaamryhumaidsuhail seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT shahparag seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT almarbouaihananhassan seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alaraimiamanyhamed seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT kairismailmohammed seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT almanjiasimmohammed seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT almallakahmedsaid seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alalawifatmakhamis seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT vaidyavidyanand seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT muqeetullahmuhammad seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alrashdihanan seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT aljamoudisaudsaidnassir seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alshaqsiasila seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alsharjiabdullah seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alshukeirihamida seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alabribadr seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT alrawahisulaiman seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT allamkisaidh seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT almanjiabdulla seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys AT aljardaniamina seroprevalenceofsarscov2antibodiesinthegeneralpopulationofomanresultsfromfoursuccessivenationwideseroepidemiologicalsurveys |